Laurie Sherman
About Laurie Sherman
Laurie Sherman serves as the Vice President of Project Leadership and Clinical Operations at Geron Corporation, bringing extensive experience in oncology clinical research and project management. She has held various leadership roles in prominent pharmaceutical companies, including GSK and Johnson & Johnson, and possesses a strong educational background in nursing and healthcare services.
Current Role at Geron Corporation
Laurie Sherman serves as the Vice President of Project Leadership and Clinical Operations at Geron Corporation. She has held this position since 2019, contributing to the company's strategic direction in clinical operations and project management. Her role involves overseeing clinical trial processes and ensuring the successful execution of oncology research initiatives.
Previous Experience at GSK
Prior to her current role, Laurie Sherman worked at GlaxoSmithKline (GSK) from 2007 to 2013. During her six years there, she held various positions including Lead Clinical Scientist, Clinical Research Leader, and Director. Her work at GSK focused on advancing clinical research and development processes.
Experience at Janssen Pharmaceutical Companies
Laurie Sherman held multiple senior director roles at The Janssen Pharmaceutical Companies of Johnson & Johnson from 2015 to 2019. Her positions included Senior Director of Compound Development Team Leader and Senior Director of Myeloid Portfolio Clinical Scientist Leader. She was responsible for leading clinical project teams and managing oncology portfolios during her tenure.
Educational Background
Laurie Sherman studied at the University of Washington, where she earned a Bachelor of Science in Nursing from 1991 to 1994. She also attended The Evergreen State College for two years from 1989 to 1991. Her educational background has provided her with a strong foundation in healthcare services.
Expertise in Clinical Trials
Laurie Sherman possesses established expertise in clinical trials and contract research organization (CRO) management. She has extensive experience leading pivotal phase 3 trials in oncology clinical research and has supported New Drug Application (NDA) and Marketing Authorization Application (MAA) submissions for several oncology compounds.